Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) was down 4.9% on Thursday . The company traded as low as $10.4415 and last traded at $10.6855. Approximately 2,074 shares were traded during trading, a decline of 86% from the average daily volume of 14,782 shares. The stock had previously closed at $11.24.
Santen Pharmaceutical Stock Up 3.9%
The business has a fifty day moving average price of $10.68 and a 200-day moving average price of $10.63.
About Santen Pharmaceutical
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Recommended Stories
- Five stocks we like better than Santen Pharmaceutical
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The day the gold market broke
- Your Bank Account Is No Longer Safe
- What a Former CIA Agent Knows About the Coming Collapse
- He just nailed another gold prediction …
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
